Cargando…

Serum CEACAM1 Elevation Correlates with Melanoma Progression and Failure to Respond to Adoptive Cell Transfer Immunotherapy

Malignant melanoma is a devastating disease whose incidences are continuously rising. The recently approved antimelanoma therapies carry new hope for metastatic patients for the first time in decades. However, the clinical management of melanoma is severely hampered by the absence of effective scree...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ortenberg, R., Sapoznik, S., Zippel, D., Shapira-Frommer, R., Itzhaki, O., Kubi, A., Zikich, D., Besser, M. J., Schachter, J., Markel, G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4673329/ https://www.ncbi.nlm.nih.gov/pubmed/26688824 http://dx.doi.org/10.1155/2015/902137

Ejemplares similares

SOX9 indirectly regulates CEACAM1 expression and immune resistance in melanoma cells
por: Ashkenazi, Shira, et al.
Publicado: (2016)

Serum CEACAM1 Correlates with Disease Progression and Survival in Malignant Melanoma Patients
por: Sivan, Sapoznik, et al.
Publicado: (2012)

Novel Anti-Melanoma Immunotherapies: Disarming Tumor Escape Mechanisms
por: Sapoznik, Sivan, et al.
Publicado: (2012)

Nicotinamide Inhibits Vasculogenic Mimicry, an Alternative Vascularization Pathway Observed in Highly Aggressive Melanoma
por: Itzhaki, Orit, et al.
Publicado: (2013)

CEACAM1 Promotes Melanoma Cell Growth through Sox-2()()
por: Ortenberg, Rona, et al.
Publicado: (2014)

Regulation of CEACAM1 Protein Expression by the Transcription Factor ETS-1 in BRAF-Mutant Human Metastatic Melanoma Cells()()
por: Kfir-Elirachman, Karin, et al.
Publicado: (2018)

Comparison of non-myeloablative lymphodepleting preconditioning regimens in patients undergoing adoptive T cell therapy
por: Nissani, Abraham, et al.
Publicado: (2021)

Development of Allogeneic NK Cell Adoptive Transfer Therapy in Metastatic Melanoma Patients: In Vitro Preclinical Optimization Studies
por: Besser, Michal J., et al.
Publicado: (2013)

Immunotherapy Discontinuation in Metastatic Melanoma: Lessons from Real-Life Clinical Experience
por: Asher, Nethanel, et al.
Publicado: (2021)

Regulation of Cancer Aggressive Features in Melanoma Cells by MicroRNAs
por: Greenberg, Eyal, et al.
Publicado: (2011)

Selection of Shared and Neoantigen-Reactive T Cells for Adoptive Cell Therapy Based on CD137 Separation
por: Seliktar-Ofir, Sivan, et al.
Publicado: (2017)

ADAR1-mediated regulation of melanoma invasion
por: Nemlich, Yael, et al.
Publicado: (2018)

Focus on Adoptive T Cell Transfer Trials in Melanoma
por: Hershkovitz, Liat, et al.
Publicado: (2010)

CEACAM1 and MICA as novel serum biomarkers in patients with acute and recurrent pericarditis
por: Markel, Gal, et al.
Publicado: (2016)

Radiotherapy may augment response to immunotherapy in metastatic uveal melanoma patients
por: Grynberg, Shirly, et al.
Publicado: (2022)

Impact of cryopreservation on CAR T production and clinical response
por: Brezinger-Dayan, Karin, et al.
Publicado: (2022)

Tumor-infiltrating lymphocytes from human prostate tumors reveal anti-tumor reactivity and potential for adoptive cell therapy
por: Yunger, Sharon, et al.
Publicado: (2019)

Differential regulation of aggressive features in melanoma cells by members of the miR-17-92 complex
por: Greenberg, Eyal, et al.
Publicado: (2014)

Better Late Than Never: The Impact of Steroidal Treatment on the Outcome of Melanoma Patients Treated with Immunotherapy
por: Bar-Hai, Neta, et al.
Publicado: (2023)

Natural Killer Lysis Receptor (NKLR)/NKLR-Ligand Matching as a Novel Approach for Enhancing Anti-Tumor Activity of Allogeneic NK Cells
por: Markel, Gal, et al.
Publicado: (2009)

Immune co-culture cell microarray – a feasible tool for high-throughput functional investigation of lymphocyte–cancer interactions
por: Baruch, Erez Nissim, et al.
Publicado: (2020)

A novel immune resistance mechanism of melanoma cells controlled by the ADAR1 enzyme
por: Galore-Haskel, Gilli, et al.
Publicado: (2015)

Real World Outcomes of Ipilimumab and Nivolumab in Patients with Metastatic Melanoma
por: Asher, Nethanel, et al.
Publicado: (2020)

CEACAM1-Mediated Inhibition of Virus Production
por: Vitenshtein, Alon, et al.
Publicado: (2016)

Is there a future for adoptive cell transfer in melanoma patients?
por: Besser, Michal J
Publicado: (2013)

CEACAM1 as a multi-purpose target for cancer immunotherapy
por: Dankner, Matthew, et al.
Publicado: (2017)

Head-to-head comparison of in-house produced CD19 CAR-T cell in ALL and NHL patients
por: Itzhaki, Orit, et al.
Publicado: (2020)

Efficacy and toxicity of Ipilimumab-Nivolumab combination therapy in elderly metastatic melanoma patients
por: Stoff, Ronen, et al.
Publicado: (2022)

Real world evidence of Lenvatinib + anti PD-1 as an advanced line for metastatic melanoma
por: Stoff, Ronen, et al.
Publicado: (2023)

Expression patterns of CEACAM5 and CEACAM6 in primary and metastatic cancers
por: Blumenthal, Rosalyn D, et al.
Publicado: (2007)

Adoption of immunotherapy in the community for patients diagnosed with metastatic melanoma
por: Krimphove, Marieke J., et al.
Publicado: (2019)

CEACAM1-4L Promotes Anchorage-Independent Growth in Melanoma
por: Löffek, Stefanie, et al.
Publicado: (2015)

Comparative analysis of CEACAM1 expression in thin melanomas with and without regression
por: Nichita, Luciana, et al.
Publicado: (2019)

Addition of Interleukin-21 for Expansion of T-Cells for Adoptive Immunotherapy of Murine Melanoma
por: Zoon, Christine Kathryn, et al.
Publicado: (2015)

Histopathological expression analysis of intercellular adhesion molecule 1 (ICAM-1) along development and progression of human melanoma
por: Galore-Haskel, Gilli, et al.
Publicado: (2017)

Role of CEACAM1 and CEACAM20 in an In Vitro Model of Prostate Morphogenesis
por: Zhang, Hui, et al.
Publicado: (2013)

CEACAMs: their role in physiology and pathophysiology
por: Kuespert, Katharina, et al.
Publicado: (2006)

Radiotherapy combined with anti-CEACAM1 immunotherapy to induce survival advantage in glioma
por: Li, Jinhu, et al.
Publicado: (2023)

Molecular and Functional Signatures Associated with CAR T Cell Exhaustion and Impaired Clinical Response in Patients with B Cell Malignancies
por: Beider, Katia, et al.
Publicado: (2022)

Metastasectomy Following Immunotherapy with Adoptive Cell Transfer for Patients with Advanced Melanoma
por: Klemen, Nicholas D., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_50lqkbgtse90pc1uol5jb3qn7j